Tuesday, August 22, 2017
 
 
Company News: Page (1) of 1 - 07/25/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

(July 25, 2017)

FIT Biotech Oy

Company release July 25, 2017 at 10:00 AM EET

Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company's board of directors has today resolved to approve Bracknor's request relating to the funding programme to convert EUR 30,000 worth of Convertible Capital Notes into the Company's K shares.


Due to the conversion of the Convertible Capital Notes, the Company issues 936,183 new K shares in the Company to Bracknor with the conversion price of EUR 0.032045 per share.

As a result of the issue of the new K shares in the Company, the total number of shares in the Company will increase to 67,017,294 shares, and the share capital of the Company will be increased by EUR 29,999.98. After the issue of the new K shares in the Company, the Company's shares will be divided in share series as follows: 66,946,830 K shares, 5,229 A shares and 65,235 D shares.

The increase of the share capital and new K shares in the Company will be registered in the Trade Register on or about July 26, 2017 and the new K shares will be admitted to trading on First North Finland on or about July 27, 2017.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Rabbe Slätis
E-mail: [email protected]

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines